Yigal Nochomovitz, PhD

Yigal Nochomovitz, PhD is a Director and SMid cap biotech analyst at Citigroup. Yigal has covered the ophthalmology space as well as other disease areas including oncology, rare disease, nephrology, and infectious disease over his career on the sell-side. Prior to Citi, Yigal worked at Oppenheimer and has covered the biotech sector as both a senior analyst and an associate since 2008. Prior to joining Oppenheimer, Yigal worked for Morgan Stanley on the Large Cap biotech team where he covered several mid-cap oncology names. Earlier in his career, Yigal worked at Rodman & Renshaw and began working on the sell-side at Susquehanna International. Prior to joining Wall Street, he was a post-doc at the Center for Studies in Physics and Biology at The Rockefeller University. Yigal holds a Ph.D. degree in Biophysics from the University of California San Francisco and has an undergraduate degree in biochemistry from Brown University.